The clinical benefit and cost effectiveness of a gastrointestinal care bundle for patients undergoing pelvic chemoradiotherapy

Not Applicable

Completed

• Conditions: Topic: Cancer; Subtopic: Bladder Cancer, Gynaecological Cancer; Disease: Bladder (advanced), Bladder (superficial), Cervix; Cancer

• Registration Number: ISRCTN78348850
• Lead Sponsor: Christie Hospital NHS Foundation Trust (UK)

Brief Summary

2020 results in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418694/ (added 04/11/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-10
• Study Completion: 2015-10-01
• Last Update Posted: 16 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

1. Age =18 years
2. Histologically confirmed cervical or bladder cancer
3. Patients undergoing potentially curative chemoradiotherapy
4. Ability to give informed consent to participate

Exclusion Criteria

1. Age <18 years
2. No histological diagnosis of cervical or bladder cancer
3. Patients unable to complete patient-reported questionnaires
4. Unable to give informed consent
5. Pre-existing GI disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gastrointestinal symptoms as determined by CTCAE pelvic symptom questionnaire; Timepoint(s): Immediately post-treatment (week 6)

Secondary Outcome Measures

Name	Time	Method
ot provided at time of regsitration